{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:44:00Z","timestamp":1795113840534,"version":"4.10.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81672554,81472417, 81972416"],"award-info":[{"award-number":["No.81672554,81472417, 81972416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Research Fund of Natural Science of Shandong Province","award":["ZR2019LZL014"],"award-info":[{"award-number":["ZR2019LZL014"]}]},{"name":"the National Key Research and Development Program of China","award":["No. 2018YFC0114703"],"award-info":[{"award-number":["No. 2018YFC0114703"]}]},{"name":"the Fundamental Research Funds of Shandong University","award":["2018JC016"],"award-info":[{"award-number":["2018JC016"]}],"id":[{"id":"https:\/\/ror.org\/0207yh398","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81772760, 82072850"],"award-info":[{"award-number":["No. 81772760, 82072850"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Shandong Taishan Scholarship","award":["NO. tsqn20161076"],"award-info":[{"award-number":["NO. tsqn20161076"]}]},{"name":"the Innovation Project of Shandong Academy of Medical Sciences","award":["2021"],"award-info":[{"award-number":["2021"]}],"id":[{"id":"https:\/\/ror.org\/05jb9pq57","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Youth Innovation Technology Plan of Shandong University","award":["No. 2019KJK003"],"award-info":[{"award-number":["No. 2019KJK003"]}],"id":[{"id":"https:\/\/ror.org\/0207yh398","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The development of castration-resistant prostate cancer (CRPC) remains a major obstacle in the treatment of prostate cancer (PCa). Dysregulated mitochondrial function has been linked to the initiation and progression of diverse human cancers. Deciphering the novel molecular mechanisms underlying mitochondrial function may provide important insights for developing novel therapeutics for CRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We investigate the expression of the protein tyrosine phosphatase receptor type F polypeptide interacting protein alpha 4 (PPFIA4) using public datasets and tumor specimens from PCa cases by immunohistochemistry. Gain- and loss-of-function studies are performed in PCa cell lines and mouse models of subcutaneous xenograft to characterize the role of PPFIA4 in CRPC. Gene expression regulation is evaluated by a series of molecular and biochemical experiments in PCa cell lines. The therapeutic effects of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor combined enzalutamide are assessed using\n                      <jats:italic>in vitro<\/jats:italic>\n                      functional assays and\n                      <jats:italic>in vivo<\/jats:italic>\n                      mouse models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We show that the increase of PPFIA4 exacerbates aggressive phenotype resembling CRPC. A fraction of PPFIA4 localizes to mitochondria and interacts with MTHFD2, a key enzyme for one-carbon metabolism. Androgen deprivation increases the translocation of PPFIA4 into mitochondria and increases the interaction between PPFIA4 and MTHFD2, which result in the elevation of tyrosine phosphorylated MTHFD2. Consequently, the levels of NADPH synthesis increase, resulting in protection against androgen deprivation-induced mitochondrial dysfunction, as well as promotion of tumor growth. Clinically, PPFIA4 expression is significantly increased in CRPC tissues compared with localized PCa ones. Importantly, an MTHFD2 inhibitor, DS18561882, combined with enzalutamide can significantly inhibit CRPC cell proliferation\n                      <jats:italic>in vitro<\/jats:italic>\n                      and tumor growth\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, our findings reveal a PPFIA4-MTHFD2 complex in mitochondria that links androgen deprivation to mitochondrial metabolism and mitochondrial dysfunction, which suggest a potential strategy to inhibit CRPC progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-022-02331-3","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:10:45Z","timestamp":1649149845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2"],"prefix":"10.1186","volume":"41","author":[{"given":"Ru","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"issue":"3","key":"2331_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","volume":"140","author":"AA Shafi","year":"2013","unstructured":"Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140(3):223\u201338.","journal-title":"Pharmacol Ther"},{"key":"2331_CR2","doi-asserted-by":"crossref","unstructured":"Crona DJ, Whang YE. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 2017;9(6).","DOI":"10.3390\/cancers9060067"},{"issue":"3","key":"2331_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","volume":"166","author":"S Vyas","year":"2016","unstructured":"Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166(3):555\u201366.","journal-title":"Cell"},{"issue":"10","key":"2331_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3365","volume":"12","author":"DC Wallace","year":"2012","unstructured":"Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685\u201398.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2331_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.5732\/cjc.011.10018","volume":"30","author":"VC Fogg","year":"2011","unstructured":"Fogg VC, Lanning NJ, Mackeigan JP. Mitochondria in cancer: At the crossroads of life and death. Chin J Cancer. 2011;30(8):526\u201339.","journal-title":"Chin J Cancer"},{"key":"2331_CR6","doi-asserted-by":"crossref","unstructured":"Mamouni K, Kallifatidis G, Lokeshwar BL. Targeting mitochondrial metabolism in prostate cancer with triterpenoids. Int J Mol Sci. 2021;22(5).","DOI":"10.3390\/ijms22052466"},{"key":"2331_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1476-4598-5-17","volume":"5","author":"LC Costello","year":"2006","unstructured":"Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: Connecting the dots. Mol Cancer. 2006;5:17.","journal-title":"Mol Cancer"},{"issue":"38","key":"2331_CR8","doi-asserted-by":"publisher","first-page":"61890","DOI":"10.18632\/oncotarget.11301","volume":"7","author":"L Ippolito","year":"2016","unstructured":"Ippolito L, Marini A, Cavallini L, Morandi A, Pietrovito L, Pintus G, et al. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. Oncotarget. 2016;7(38):61890\u2013904.","journal-title":"Oncotarget"},{"key":"2331_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2019.12.017","volume":"471","author":"YG Lee","year":"2020","unstructured":"Lee YG, Nam Y, Shin KJ, Yoon S, Park WS, Joung JY, et al. Androgen-induced expression of drp1 regulates mitochondrial metabolic reprogramming in prostate cancer. Cancer Lett. 2020;471:72\u201387.","journal-title":"Cancer Lett"},{"issue":"13","key":"2331_CR10","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/emboj.2011.158","volume":"30","author":"CE Massie","year":"2011","unstructured":"Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30(13):2719\u201333.","journal-title":"EMBO J"},{"issue":"1","key":"2331_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1476-4598-12-145","volume":"12","author":"K Grupp","year":"2013","unstructured":"Grupp K, Jedrzejewska K, Tsourlakis MC, Koop C, Wilczak W, Adam M, et al. High mitochondria content is associated with prostate cancer disease progression. Mol Cancer. 2013;12(1):145.","journal-title":"Mol Cancer"},{"issue":"6","key":"2331_CR12","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1158\/0008-5472.CAN-10-1791","volume":"71","author":"D Zhang","year":"2011","unstructured":"Zhang D, He D, Xue Y, Wang R, Wu K, Xie H, et al. Prlz protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of stat3\/bcl-2 pathway. Cancer Res. 2011;71(6):2193\u2013202.","journal-title":"Cancer Res"},{"issue":"10","key":"2331_CR13","doi-asserted-by":"publisher","first-page":"e1955","DOI":"10.1038\/cddis.2015.289","volume":"6","author":"J Zhou","year":"2015","unstructured":"Zhou J, Ning Z, Wang B, Yun EJ, Zhang T, Pong RC, et al. Dab2ip loss confers the resistance of prostate cancer to androgen deprivation therapy through activating stat3 and inhibiting apoptosis. Cell Death Dis. 2015;6(10):e1955.","journal-title":"Cell Death Dis"},{"key":"2331_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.freeradbiomed.2020.07.009","volume":"160","author":"F Fontana","year":"2020","unstructured":"Fontana F, Raimondi M, Marzagalli M, Audano M, Beretta G, Procacci P, et al. Mitochondrial functional and structural impairment is involved in the antitumor activity of \u03b4-tocotrienol in prostate cancer cells. Free Radic Biol Med. 2020;160:376\u201390.","journal-title":"Free Radic Biol Med"},{"issue":"15","key":"2331_CR15","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1002\/cne.22665","volume":"519","author":"SA Spangler","year":"2011","unstructured":"Spangler SA, Jaarsma D, De Graaff E, Wulf PS, Akhmanova A, Hoogenraad CC. Differential expression of liprin-\u03b1 family proteins in the brain suggests functional diversification. J Comp Neurol. 2011;519(15):3040\u201360.","journal-title":"J Comp Neurol"},{"issue":"25","key":"2331_CR16","doi-asserted-by":"publisher","first-page":"15611","DOI":"10.1074\/jbc.273.25.15611","volume":"273","author":"C Serra-Pag\u00e8s","year":"1998","unstructured":"Serra-Pag\u00e8s C, Medley QG, Tang M, Hart A, Streuli M. Liprins, a family of lar transmembrane protein-tyrosine phosphatase-interacting proteins. J Biol Chem. 1998;273(25):15611\u201320.","journal-title":"J Biol Chem"},{"issue":"12","key":"2331_CR17","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1002\/j.1460-2075.1995.tb07282.x","volume":"14","author":"C Serra-Pag\u00e8s","year":"1995","unstructured":"Serra-Pag\u00e8s C, Kedersha NL, Fazikas L, Medley Q, Debant A, Streuli M. The lar transmembrane protein tyrosine phosphatase and a coiled-coil lar-interacting protein co-localize at focal adhesions. EMBO J. 1995;14(12):2827\u201338.","journal-title":"EMBO J"},{"issue":"17","key":"2331_CR18","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1016\/j.yexcr.2010.06.022","volume":"316","author":"S Mattauch","year":"2010","unstructured":"Mattauch S, Sachs M, Behrens J. Liprin-\u03b14 is a new hypoxia-inducible target gene required for maintenance of cell-cell contacts. Exp Cell Res. 2010;316(17):2883\u201392.","journal-title":"Exp Cell Res"},{"issue":"1","key":"2331_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0896-6273(02)00640-2","volume":"34","author":"M Wyszynski","year":"2002","unstructured":"Wyszynski M, Kim E, Dunah AW, Passafaro M, Valtschanoff JG, Serra-Pag\u00e8s C, et al. Interaction between grip and liprin-alpha\/syd2 is required for ampa receptor targeting. Neuron. 2002;34(1):39\u201352.","journal-title":"Neuron"},{"issue":"12","key":"2331_CR20","first-page":"6649","volume":"37","author":"A Yamasaki","year":"2017","unstructured":"Yamasaki A, Nakayama K, Imaizumi A, Kawamoto M, Fujimura A, Oyama Y, et al. Liprin-\u03b14 as a possible new therapeutic target for pancreatic cancer. Anticancer Res. 2017;37(12):6649\u201354.","journal-title":"Anticancer Res"},{"issue":"3","key":"2331_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.21873\/anticanres.13227","volume":"39","author":"H Onishi","year":"2019","unstructured":"Onishi H, Yamasaki A, Nakamura K, Ichimiya S, Yanai K, Umebayashi M, et al. Liprin-\u03b14 as a new therapeutic target for sclc as an upstream mediator of hif1\u03b1. Anticancer Res. 2019;39(3):1179\u201384.","journal-title":"Anticancer Res"},{"issue":"1","key":"2331_CR22","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1038\/s41598-020-64326-4","volume":"10","author":"P Gottmann","year":"2020","unstructured":"Gottmann P, Ouni M, Zellner L, J\u00e4hnert M, Rittig K, Walther D, et al. Polymorphisms in mirna binding sites involved in metabolic diseases in mice and humans. Sci Rep. 2020;10(1):7202.","journal-title":"Sci Rep"},{"key":"2331_CR23","doi-asserted-by":"publisher","first-page":"653200","DOI":"10.3389\/fonc.2021.653200","volume":"11","author":"J Huang","year":"2021","unstructured":"Huang J, Yang M, Liu Z, Li X, Wang J, Fu N, et al. Ppfia4 promotes colon cancer cell proliferation and migration by enhancing tumor glycolysis. Front Oncol. 2021;11:653200.","journal-title":"Front Oncol"},{"issue":"6","key":"2331_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/jnci\/djy160","volume":"111","author":"HQ Ju","year":"2019","unstructured":"Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, et al. Modulation of redox homeostasis by inhibition of mthfd2 in colorectal cancer: Mechanisms and therapeutic implications. J Natl Cancer Inst. 2019;111(6):584\u201396.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2331_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.stemcr.2020.06.018","volume":"15","author":"L Yue","year":"2020","unstructured":"Yue L, Pei Y, Zhong L, Yang H, Wang Y, Zhang W, et al. Mthfd2 modulates mitochondrial function and DNA repair to maintain the pluripotency of mouse stem cells. Stem Cell Reports. 2020;15(2):529\u201345.","journal-title":"Stem Cell Reports"},{"issue":"21","key":"2331_CR26","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/0008-5472.CAN-17-0150","volume":"77","author":"L Wang","year":"2017","unstructured":"Wang L, Song G, Zhang X, Feng T, Pan J, Chen W, et al. Padi2-mediated citrullination promotes prostate cancer progression. Cancer Res. 2017;77(21):5755\u201368.","journal-title":"Cancer Res"},{"issue":"4","key":"2331_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","volume":"81","author":"L Gao","year":"2021","unstructured":"Gao L, Zhang W, Zhang J, Liu J, Sun F, Liu H, et al. Kif15-mediated stabilization of ar and ar-v7 contributes to enzalutamide resistance in prostate cancer. Cancer Res. 2021;81(4):1026\u201339.","journal-title":"Cancer Res"},{"issue":"36","key":"2331_CR28","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1038\/onc.2014.401","volume":"34","author":"L Wang","year":"2015","unstructured":"Wang L, Song G, Chang X, Tan W, Pan J, Zhu X, et al. The role of txndc5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway. Oncogene. 2015;34(36):4735\u201345.","journal-title":"Oncogene"},{"issue":"12","key":"2331_CR29","doi-asserted-by":"publisher","first-page":"13398","DOI":"10.1096\/fj.201901366R","volume":"33","author":"Y Wang","year":"2019","unstructured":"Wang Y, Agarwal E, Bertolini I, Ghosh JC, Seo JH, Altieri DC. Idh2 reprograms mitochondrial dynamics in cancer through a hif-1\u03b1-regulated pseudohypoxic state. FASEB J. 2019;33(12):13398\u2013411.","journal-title":"FASEB J"},{"issue":"1","key":"2331_CR30","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1038\/s41467-018-07411-7","volume":"9","author":"H Geng","year":"2018","unstructured":"Geng H, Xue C, Mendonca J, Sun XX, Liu Q, Reardon PN, et al. Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen\/ar-targeted therapy. Nat Commun. 2018;9(1):4972.","journal-title":"Nat Commun"},{"key":"2331_CR31","doi-asserted-by":"publisher","first-page":"625452","DOI":"10.3389\/fonc.2021.625452","volume":"11","author":"Z Xu","year":"2021","unstructured":"Xu Z, Xu L, Liu L, Li H, Jin J, Peng M, et al. A glycolysis-related five-gene signature predicts biochemical recurrence-free survival in patients with prostate adenocarcinoma. Front Oncol. 2021;11:625452.","journal-title":"Front Oncol"},{"issue":"2","key":"2331_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/0008-5472.CAN-16-1204","volume":"77","author":"\u00c9 Audet-Walsh","year":"2017","unstructured":"Audet-Walsh \u00c9, Yee T, McGuirk S, Vernier M, Ouellet C, St-Pierre J, et al. Androgen-dependent repression of err\u03b3 reprograms metabolism in prostate cancer. Cancer Res. 2017;77(2):378\u201389.","journal-title":"Cancer Res"},{"issue":"3","key":"2331_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.01.018","volume":"35","author":"M Reina-Campos","year":"2019","unstructured":"Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, et al. Increased serine and one-carbon pathway metabolism by pkc\u03bb\/\u03b9 deficiency promotes neuroendocrine prostate cancer. Cancer Cell. 2019;35(3):385\u2013400.e9.","journal-title":"Cancer Cell"},{"issue":"15","key":"2331_CR34","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/0008-5472.CAN-20-3956","volume":"81","author":"N P\u00e4llmann","year":"2021","unstructured":"P\u00e4llmann N, Deng K, Livg\u00e5rd M, Tesikova M, Jin Y, Frengen NS, et al. Stress-mediated reprogramming of prostate cancer one-carbon cycle drives disease progression. Cancer Res. 2021;81(15):4066\u201378.","journal-title":"Cancer Res"},{"issue":"1","key":"2331_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","volume":"25","author":"GS Ducker","year":"2017","unstructured":"Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab. 2017;25(1):27\u201342.","journal-title":"Cell Metab"},{"issue":"8","key":"2331_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41419-020-02825-y","volume":"11","author":"X Wan","year":"2020","unstructured":"Wan X, Wang C, Huang Z, Zhou D, Xiang S, Qi Q, et al. Cisplatin inhibits sirt3-deacetylation mthfd2 to disturb cellular redox balance in colorectal cancer cell. Cell Death Dis. 2020;11(8):649.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2331_CR37","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.bbabio.2012.01.014","volume":"1817","author":"E Hebert-Chatelain","year":"2012","unstructured":"Hebert-Chatelain E, Jose C, Gutierrez Cortes N, Dupuy JW, Rocher C, Dachary-Prigent J, et al. Preservation of nadh ubiquinone-oxidoreductase activity by src kinase-mediated phosphorylation of ndufb10. Biochim Biophys Acta. 2012;1817(5):718\u201325.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2331_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.biocel.2012.08.014","volume":"45","author":"E Hebert-Chatelain","year":"2013","unstructured":"Hebert-Chatelain E. Src kinases are important regulators of mitochondrial functions. Int J Biochem Cell Biol. 2013;45(1):90\u20138.","journal-title":"Int J Biochem Cell Biol"},{"issue":"22","key":"2331_CR39","doi-asserted-by":"publisher","first-page":"10204","DOI":"10.1021\/acs.jmedchem.9b01113","volume":"62","author":"J Kawai","year":"2019","unstructured":"Kawai J, Toki T, Ota M, Inoue H, Takata Y, Asahi T, et al. Discovery of a potent, selective, and orally available mthfd2 inhibitor (ds18561882) with in vivo antitumor activity. J Med Chem. 2019;62(22):10204\u201320.","journal-title":"J Med Chem"},{"issue":"3","key":"2331_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/cr.2017.155","volume":"28","author":"PE Porporato","year":"2018","unstructured":"Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265\u201380.","journal-title":"Cell Res"},{"issue":"11","key":"2331_CR41","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/carcin\/bgy133","volume":"39","author":"J Xiao","year":"2018","unstructured":"Xiao J, Cohen P, Stern MC, Odedina F, Carpten J, Reams R. Mitochondrial biology and prostate cancer ethnic disparity. Carcinogenesis. 2018;39(11):1311\u20139.","journal-title":"Carcinogenesis"},{"issue":"4","key":"2331_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000487188","volume":"64","author":"N Apaiajai","year":"2018","unstructured":"Apaiajai N, Chunchai T, Jaiwongkam T, Kerdphoo S, Chattipakorn SC, Chattipakorn N. Testosterone deprivation aggravates left-ventricular dysfunction in male obese insulin-resistant rats via impairing cardiac mitochondrial function and dynamics proteins. Gerontology. 2018;64(4):333\u201343.","journal-title":"Gerontology"},{"key":"2331_CR43","doi-asserted-by":"crossref","unstructured":"Sarniak A, Lipi\u0144ska J, Tytman K, Lipi\u0144ska S. Endogenous mechanisms of reactive oxygen species (ros) generation. Postepy Hig Med Dosw (Online) 2016;70(0):1150-1165.","DOI":"10.5604\/17322693.1224259"},{"issue":"6","key":"2331_CR44","doi-asserted-by":"publisher","first-page":"e68003","DOI":"10.1371\/journal.pone.0068003","volume":"8","author":"DG Burton","year":"2013","unstructured":"Burton DG, Giribaldi MG, Munoz A, Halvorsen K, Patel A, Jorda M, et al. Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells. PLoS One. 2013;8(6):e68003.","journal-title":"PLoS One"},{"issue":"12","key":"2331_CR45","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1210\/en.2002-220327","volume":"143","author":"ST Pang","year":"2002","unstructured":"Pang ST, Dillner K, Wu X, Pousette A, Norstedt G, Flores-Morales A. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology. 2002;143(12):4897\u2013906.","journal-title":"Endocrinology"},{"issue":"2","key":"2331_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/onc.2009.322","volume":"29","author":"M Shiota","year":"2010","unstructured":"Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, et al. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through twist1 and androgen receptor overexpression. Oncogene. 2010;29(2):237\u201350.","journal-title":"Oncogene"},{"issue":"Pt 18","key":"2331_CR47","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1242\/jcs.054155","volume":"122","author":"C Asperti","year":"2009","unstructured":"Asperti C, Astro V, Totaro A, Paris S, de Curtis I. Liprin-alpha1 promotes cell spreading on the extracellular matrix by affecting the distribution of activated integrins. J Cell Sci. 2009;122(Pt 18):3225\u201332.","journal-title":"J Cell Sci"},{"issue":"6","key":"2331_CR48","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.yexcr.2010.01.017","volume":"316","author":"C Asperti","year":"2010","unstructured":"Asperti C, Pettinato E, de Curtis I. Liprin-alpha1 affects the distribution of low-affinity beta1 integrins and stabilizes their permanence at the cell surface. Exp Cell Res. 2010;316(6):915\u201326.","journal-title":"Exp Cell Res"},{"issue":"1","key":"2331_CR49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41467-019-13949-x","volume":"11","author":"X Xie","year":"2020","unstructured":"Xie X, Luo L, Liang M, Zhang W, Zhang T, Yu C, et al. Structural basis of liprin-\u03b1-promoted lar-rptp clustering for modulation of phosphatase activity. Nat Commun. 2020;11(1):169.","journal-title":"Nat Commun"},{"issue":"10","key":"2331_CR50","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc.2016.81","volume":"16","author":"M Yang","year":"2016","unstructured":"Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016;16(10):650\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2331_CR51","doi-asserted-by":"publisher","first-page":"e12718","DOI":"10.1111\/cpr.12718","volume":"53","author":"L Liu","year":"2020","unstructured":"Liu L, Wang F, Tong Y, Li LF, Liu Y, Gao WQ. Pentamidine inhibits prostate cancer progression via selectively inducing mitochondrial DNA depletion and dysfunction. Cell Prolif. 2020;53(1):e12718.","journal-title":"Cell Prolif"},{"issue":"13","key":"2331_CR52","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cmdc.201700196","volume":"12","author":"H Wang","year":"2017","unstructured":"Wang H, Huwaimel B, Verma K, Miller J, Germain TM, Kinarivala N, et al. Synthesis and antineoplastic evaluation of mitochondrial complex ii (succinate dehydrogenase) inhibitors derived from atpenin a5. ChemMedChem. 2017;12(13):1033\u201344.","journal-title":"ChemMedChem"},{"issue":"1","key":"2331_CR53","doi-asserted-by":"publisher","first-page":"9764","DOI":"10.1038\/s41598-020-66428-5","volume":"10","author":"SA Dyshlovoy","year":"2020","unstructured":"Dyshlovoy SA, Kudryashova EK, Kaune M, Makarieva TN, Shubina LK, Busenbender T, et al. Urupocidin c: A new marine guanidine alkaloid which selectively kills prostate cancer cells via mitochondria targeting. Sci Rep. 2020;10(1):9764.","journal-title":"Sci Rep"},{"issue":"3","key":"2331_CR54","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/jpet.119.261040","volume":"371","author":"J Cheng","year":"2019","unstructured":"Cheng J, Moore S, Gomez-Galeno J, Lee DH, Okolotowicz KJ, Cashman JR. A novel small molecule inhibits tumor growth and synergizes effects of enzalutamide on prostate cancer. J Pharmacol Exp Ther. 2019;371(3):703\u201312.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2331_CR55","first-page":"390","volume":"9","author":"J Cheng","year":"2019","unstructured":"Cheng J, Okolotowicz KJ, Ryan D, Mose E, Lowy AM, Cashman JR. Inhibition of invasive pancreatic cancer: Restoring cell apoptosis by activating mitochondrial p53. Am J Cancer Res. 2019;9(2):390\u2013405.","journal-title":"Am J Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02331-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02331-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02331-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T21:10:15Z","timestamp":1666473015000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02331-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2331"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02331-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"1 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of clinical samples was approved by the ethics committee of Shandong University and informed consent was obtained from all patients. All animal experimental protocols were performed following the Ethical Animal Care and Use Committee of Shandong University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}